The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index; 111 of the 156 sources its claims cite were checked for support.
Recent Progress in Research on Mitochondrion-Targeted Antifungal Drugs: a Review
Open accessAbstract
Fungal infections, which commonly occur in immunocompromised patients, can cause high morbidity and mortality. Antifungal agents act by disrupting the cell membrane, inhibiting nucleic acid synthesis and function, or inhibiting β-1,3-glucan synthase.
Overview
CoChat Summary
TL;DR
This review summarizes antifungal agents that target mitochondrial components, especially electron transport chain complexes, DHODH, and Mir1, and catalogs their stages, spectra, MICs, in vivo efficacy, and selectivity. It concludes that mitochondria are promising but under-exploited antifungal targets, with only T-2307 and F90138 in clinical trials and most candidates still preclinical.
Key findings
- T-2307 (phase II) inhibits mitochondrial respiratory chain CIII and CIV; reported MICs are 0.00025–0.0039 μg/mL against Candida, 0.125–4 μg/mL against Aspergillus, and 0.0039–0.06 μg/mL against Cryptococcus, with >1,000-fold selectivity.
- F90138/olorofim (phase IIb) targets DHODH and is active against Aspergillus and Coccidioides with MIC ≤0.06 μg/mL; it shows >2,200-fold selectivity for A. fumigatus DHODH over the mammalian enzyme but is inactive against yeasts and Mucorales.
- Preclinical candidates include ilicicolin H (cytochrome bc1/CIII; MICs 0.01–5.0 μg/mL for Candida, 0.1–1.56 μg/mL for Cryptococcus, 0.08 μg/mL for Aspergillus), ML316 (Mir1; Candida MIC 0.008–1.156 μg/mL; reduced oropharyngeal candidiasis burden 100-fold alone and >1,000-fold with fluconazole), and Inz-5 (CIII; C. albicans MIC50 0.15 μg/mL; 27.8-fold selectivity).
- Natural products and antimicrobial peptides such as berberine, resveratrol, chiloscyphenol A, floricolin C, kalopanaxsaponin A, mefloquine derivatives, papaya seed extract, rosmarinic acid, P-113Du/P-113Tri, and ToAP2D affect mitochondrial function; many still lack specific targets, while P-113Du and P-113Tri inhibit NADH dehydrogenase/CI.
Methods
- Narrative review; no primary experimental design. It synthesizes published studies on mitochondrion-targeted antifungal drugs and mitochondrial targets.
- Data source: literature summarized in Table 1, covering agent, development stage, target, antifungal spectrum, in vitro MIC, in vivo efficacy, cytotoxicity IC50, and selectivity.
- Main analysis: qualitative synthesis of mechanisms, selectivity, and development stage; no systematic review or meta-analysis is described.
Limitations
- Stated: only a few drugs are under clinical trials; most agents target mitochondrial dysfunction broadly, and studies on other mitochondrial processes as targets are lacking. Exact targets of some compounds, such as 19ak and SM21, remain unclear, and some candidates have poor plasma or microsome stability.
- Stated: the close evolutionary relationship between fungi and humans makes selective mitochondrial targeting challenging; clinical candidates do not act on fungus-specific proteins but are highly selective toward fungal cells.
- Evident: as a narrative review, it lacks systematic search or inclusion criteria; many candidates are preclinical, and several Table 1 entries are “N/M,” limiting comparative efficacy and safety conclusions.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
97 Valid · 3 Not valid · 30 Not checked · 14 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Seven CTG clade-specific mitochondrial subunit proteins on the ETC are required for the expression of various ETC complexes and respiratory function and may be potential antifungal drug targets (12).”
§ Recent Progress in Research on Mitochondrion-Targeted Antifungal Drugs: a Review > ADVANTAGES OF MITOCHONDRIA AS TARGETS OF ANTIFUNGAL DRUGS
What the sources say
- Partly supportedcites [12] Sun N, Parrish RS, Calderone RA, Fonzi WA. 2019. Unique, diverged, and conserved mitochondrial functions influencing Candida albicans respiration. mBio 10. doi: 10.1128/mBio.00300-19. PMC6593398 31239372 sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) says seven CTG clade-specific proteins localized to mitochondria and were required for expression of various ETC complexes; the Discussion says they have essential roles in respiration. But the Discussion identifies only Nuo3 and Nuo4 as likely ETC subunits, leaves the others’ biochemical roles unresolved, and does not identify the seven proteins as potential antifungal drug targets. (LLM, conf=0.88)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“8.0% to 9.3% of Candida glabrata bloodstream isolates showed resistance to echinocandin”
§ Recent Progress in Research on Mitochondrion-Targeted Antifungal Drugs: a Review > INTRODUCTION
What the sources say
- Supportedcites [5] Perlin DS. 2014. Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management. Drugs 74: 1573– 1585. doi: 10.1007/s40265-014-0286-5. 25255923 PMC4201113 source
Section 3, ‘Epidemiology of Echinocandin Resistance,’ reports that the SENTRY surveillance program found 8.0–9.3% echinocandin resistance among 1,669 C. glabrata bloodstream isolates collected in 2006–2010. This directly supports the cited percentage and population. (LLM, conf=0.95)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Several studies have unraveled the mechanism of action of T-2307 and revealed that it is an inhibitor of mitochondrial respiratory chain CIII and CIV.”
§ Recent Progress in Research on Mitochondrion-Targeted Antifungal Drugs: a Review > MITOCHONDRIA-TARGETED ANTIFUNGALS WITH SPECIFIC TARGETS > Arylamidine T-2307.
What the sources say
- Partly supportedcites [35] Wiederhold NP. 2021. Review of T-2307, an investigational agent that causes collapse of fungal mitochondrial membrane potential. J Fungi (Basel) 7: 130. doi: 10.3390/jof7020130. 33670132 PMC7916847 sourceExperimental — accuracy not yet measured
The Structure and Mechanism of Action section reports that T-2307 inhibits the yeast mitochondrial respiratory chain, with further work suggesting that inhibition occurs mainly at complexes III and IV. The citing sentence presents that more tentative, yeast-specific finding as an unqualified established mechanism. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Although the antifungal drug candidates ilicicolin H, Inz-1 and Inz-5 act by inhibiting the highly conserved cytochrome bc1 reductase of CIII, the selectivity of ilicicolin H is approximately 50 times higher than that of Inz-1 or Inz-5.”
§ Recent Progress in Research on Mitochondrion-Targeted Antifungal Drugs: a Review > ANTIMICROBIAL PEPTIDES AFFECTING MITOCHONDRIAL FUNCTION > Conclusions and perspectives.
What the sources say
- Partly supportedcites [48] Vincent BM, Langlois J-B, Srinivas R, Lancaster AK, Scherz-Shouval R, Whitesell L, Tidor B, Buchwald SL, Lindquist S. 2016. A fungal-selective cytochrome bc1 inhibitor impairs virulence and prevents the evolution of drug resistance. Cell Chem Biol 23: 978– 991. doi: 10.1016/j.chembiol.2016.06.016. 27524297 PMC5159300 sourceExperimental — accuracy not yet measured
The Results section reports selectivity for Inz-1 and a selectivity index of 28 for Inz-5. In our copy, ilicicolin H appears only in a reference title; the paper does not give its selectivity or make the claimed approximately 50-fold comparison. (LLM, conf=0.83)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“SM21 significantly improved the murine survival rate in an invasive candidiasis model by 100% in 5 days.”
§ Recent Progress in Research on Mitochondrion-Targeted Antifungal Drugs: a Review > MITOCHONDRIA-RELATED ANTIFUNGAL HITS > SM21.
What the sources say
- Supportedcites [52] Wong SSW, Kao RYT, Yuen KY, Wang Y, Yang D, Samaranayake LP, Seneviratne CJ. 2014. In vitro and in vivo activity of a novel antifungal small molecule against Candida infections. PLoS One 9: e85836. doi: 10.1371/journal.pone.0085836. 24465737 PMC3899067 source
The Results section, “SM21 improves survival in a mouse model of systemic candidiasis” (Figure 12A; page not provided), reports 100% survival in SM21-treated mice versus 0% in untreated mice at day 5. This supports the claimed improvement in the murine systemic candidiasis model. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
64 more claims · 38 with their cited sources checked
Create a free account to see all 144 claims and to verify the 5 references still open.
- It may state two separate claims as one. 66
- Probably not a substantial claim. 12
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Recent Progress in Research on Mitochondrion-Targeted Antifungal Drugs: a Review > NATURAL ANTIFUNGAL HITS AFFECTING MITOCHONDRIAL FUNCTION
“RA showed potent anticandidal activity, with an MIC range of 0.1 to 0.2 mg/mL (76).”
§ Recent Progress in Research on Mitochondrion-Targeted Antifungal Drugs: a Review > ADVANTAGES OF MITOCHONDRIA AS TARGETS OF ANTIFUNGAL DRUGS
“| Rosmarinic acid | Preclinical | Mitochondrial function | Candida | 0.1–0.2 | N/M | 360.31 (HepG2) | 1,801.55–3,603.1 | 75, 76 |”
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Recent Progress in Research on Mitochondrion-Targeted Antifungal Drugs: a Review > MITOCHONDRIA-TARGETED ANTIFUNGALS WITH SPECIFIC TARGETS > Arylamidine T-2307.
“the MIC of T-2307 ranges from 0.00025 to 0.0039 μg/mL against Candida species”
§ Recent Progress in Research on Mitochondrion-Targeted Antifungal Drugs: a Review > ADVANTAGES OF MITOCHONDRIA AS TARGETS OF ANTIFUNGAL DRUGS
“| T-2307 | Phase II clinical trials | CIII, CIV | Candida | 0.00025–>4 | Murine models of invasive candidiasis, aspergillosis, and cryptococcosis | N/Mc | >1,000 | 28–31, 35, 39 |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Recent Progress in Research on Mitochondrion-Targeted Antifungal Drugs: a Review > ADVANTAGES OF MITOCHONDRIA AS TARGETS OF ANTIFUNGAL DRUGS
“Moreover, Nuo1 and Nuo2 are fungus-specific CI subunits, which may be more suitable for antifungal targets (8, 16).”
§ Recent Progress in Research on Mitochondrion-Targeted Antifungal Drugs: a Review > ANTIMICROBIAL PEPTIDES AFFECTING MITOCHONDRIAL FUNCTION > Conclusions and perspectives.
“(iii) broadly specific proteins in fungi, algae, plants but not in mammals (Nuo1)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Recent Progress in Research on Mitochondrion-Targeted Antifungal Drugs: a Review > MITOCHONDRIA-TARGETED ANTIFUNGALS WITH SPECIFIC TARGETS > Ilicicolin H.
“inhibition of Candida, Cryptococcus, and Aspergillus spp., with MICs ranging from 0.04 to 1.56 μg/mL (44).”
§ Recent Progress in Research on Mitochondrion-Targeted Antifungal Drugs: a Review > ADVANTAGES OF MITOCHONDRIA AS TARGETS OF ANTIFUNGAL DRUGS
“| Ilicicolin H | Preclinical | Cytochrome bc1 reductase (CIII) | Candida | 0.01–5.0 | Murine models of invasive candidiasis and cryptococcosis | N/M | >1,000 | 44, 46 |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Recent Progress in Research on Mitochondrion-Targeted Antifungal Drugs: a Review > MITOCHONDRIA-RELATED ANTIFUNGAL HITS > 19ak.
“19ak also has low cytotoxicity (IC50, 26.79 mg/mL in the HK2 cell line) and a high selectivity index (214.32)”
§ Recent Progress in Research on Mitochondrion-Targeted Antifungal Drugs: a Review > ADVANTAGES OF MITOCHONDRIA AS TARGETS OF ANTIFUNGAL DRUGS
“| 19ak | Preclinical | CI | Candida | 0.125–1 | G. mellonella model of C. albicans infection | 26.79 (HK2) | 214.32 (HK2) | 49 – 51 |”
Citations
Cites
Zielonka, J., Joseph, J., Sikora, A., Hardy, M., Ouari, O., Vasquez-Vivar, J., Cheng, G., Lopez, M., & Kalyanaraman, B. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00042 · Cited by 1,683 · cited 1×
“The mitochondrion is considered a therapeutic target for a variety of diseases (cancer, cardiovascular diseases, neurological diseases, and infections), not only because of its important functions in cell viability but also because of its mitochondrial targeting characteristics (22).”
BackgroundMitochondrial proteins: from biogenesis to functional networks
Pfanner, N., Warscheid, B., & Wiedemann, N. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0092-0 · Cited by 1,028 · cited 1×
“The realization of diverse mitochondrial functions depends on the action of functional proteins (10).”
BackgroundHealth benefits of resveratrol: Evidence from clinical studies
Singh, A. P., Singh, R., Verma, S. S., Rai, V., Kaschula, C. H., Maiti, P., & Gupta, S. C. (2019) · Medicinal Research Reviews · doi:10.1002/med.21565 · Cited by 523 · cited 1×
“Although clinical trials have proved the safety of resveratrol in the human body, further in vivo research on its use for the treatment of fungal infections is still needed (66).”
BackgroundAntibacterial and antifungal properties of resveratrol
Vestergaard, M., & Ingmer, H. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2019.02.015 · Cited by 482 · cited 1×
“300 m g/mL (60, 61).”
Mechanisms and regulation of protein synthesis in mitochondria
Kummer, E., & Ban, N. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00332-2 · Cited by 349 · cited 1×
“dria, most of which are encoded by the cell nucleus and highly conserved among species (9).”
BackgroundIsavuconazole: A New Broad-Spectrum Triazole Antifungal Agent
Miceli, M. H., & Kauffman, C. A. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ571 · Cited by 338 · cited 1×
“tions, adverse effects, and cross-resistance limit their clinical applicability (6).”
A Review of the Anti-Inflammatory Effects of Rosmarinic Acid on Inflammatory Diseases
Luo, C., Zou, L., Sun, H., Peng, J., Gao, C., Bao, L., Ji, R., Jin, Y., & Sun, S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00153 · Cited by 336 · cited 1×
“for its therapeutic mechanism of action on diseases related to mitochondrial dysfunction (75).”
BackgroundF901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase
Oliver, J. D., Sibley, G. E. M., Beckmann, N., Dobb, K. S., Slater, M. J., McEntee, L., du Pré, S., Livermore, J., Bromley, M. J., Wiederhold, N. P., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608304113 · Cited by 289 · cited 1×
“F90138 targets DHODH, an essential mitochondrial enzyme that catalyzes the conversion of dihydroorotate to orotate in the de novo pyrimidine biosynthesis pathway (40).”
BackgroundZinovkin, R. A., & Zamyatnin, A. A. (2019) · Current Molecular Pharmacology · doi:10.2174/1874467212666181127151059 · Cited by 209 · cited 2×
“Several effective strategies for mitochondrial targeting have already been developed (23, 24).”
Hope on the Horizon: Novel Fungal Treatments in Development
Rauseo, A. M., Coler-Reilly, A., Larson, L., & Spec, A. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa016 · Cited by 199
Cited by
Next-generation antifungal drugs: Mechanisms, efficacy, and clinical prospects
Lu, X., Zhou, J., Ming, Y., Wang, Y., He, R., Li, Y., Feng, L., Zeng, B., Du, Y., & Wang, C. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.06.013 · Cited by 53
“Additionally, antifungal drugs targeting intracellular proteins hinder fungal proliferation by inhibiting nucleic acid synthesis, disrupting the electron transport chain, or impairing microtubule dynamics 10,11 (Fig.”
The progress and future of the treatment of Candida albicans infections based on nanotechnology
Gao, Y., Cao, Q., Xiao, Y., Wu, Y., Ding, L., Huang, H., Li, Y., Yang, J., & Meng, L. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02841-6 · Cited by 33
“Compared to the model yeast Saccharomyces cerevisiae , the mitochondria of fungal pathogens are different [89].”
ResultWeerasinghe, H., Stölting, H., Rose, A. J., & Traven, A. (2024) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00171-22 · Cited by 30
“For example, T-2307 which inhibits mitochondrial respiration at complexes III and IV in the respiratory chain (107) and F90138 which targets A. fumigatus pyrimidine biosynthe sis enzyme dihydroorotate dehydrogenase (DHODH) are in clinical trials, reviewed in reference (108).”
Deciphering the role of mitochondria in human fungal drug resistance
Ma, Y., Zhou, Y., Jia, T., Zhuang, Z., Xue, P., & Yang, L. (2025) · Mycology: An International Journal on Fungal Biology · doi:10.1080/21501203.2025.2473507 · Cited by 13
“Recent advancements in drug discovery have led to significant progress in the development of mitochon-drion-targeted antifungal agents, highlighting the potential of various novel compounds in combating fungal infections (Qin et al. 2023).”
Yang, Y., Zeng, Y., Liu, Z., & Huang, J. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1714998 · Cited by 16
Metadata
- Authors
- Qin, Y., Wang, J., Lv, Q., & Han, B.
- Affiliations
- Fudan University (CN)
- Second Military Medical University (CN)
- Corresponding author
- Lv, Quanzhen
- Han, Bing
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2023-06-15
- Volume
- 67
- Issue
- 6
- Pages
- e0000323-e0000323
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC10269089
- OpenAlex
- W4376873051
- Cited by
- 38
- References
- 84
- Citations by year
- 2026: 14 · 2025: 13 · 2024: 11
- FWCI
- 1.80
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (vor)
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- MOST | National Natural Science Foundation of China (82204468)
- Shanghai Minhang District Health Commission (2021MW01)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Keywords
- fungal infection, mitochondrial electron transport chain, mitochondrial respiration, reactive oxygen species, intracellular ATP, antifungal resistance, immunocompromised patients, lead compounds
- MeSH terms
- Antifungal Agents, Fungal Proteins, Humans, Mitochondria, Mycoses, Drug Delivery Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recent Progress in Research on Mitochondrion-Targeted Antifungal Drugs: a Review. https://app.cochat.ai/papers/10.1128/aac.00003-23
- The paper
- Qin, Y., Wang, J., Lv, Q., & Han, B. (2023). Recent Progress in Research on Mitochondrion-Targeted Antifungal Drugs: a Review. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00003-23
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.